Objective: We aimed to review all cytological specimens with Hürthle cells (HC) diagnosed in our institution, identify cytological features related to neoplastic (adenoma or carcinoma) and malignant histology, and discuss the role of clinicopathological findings and clinical management in these cases. Study Design: We included 359 thyroid fine-needle aspiration cytology cases in our study. We reviewed the clinical and cytological features of surgical cases and correlated them with histological diagnosis. We also reviewed the literature on this issue. Results: We found a significant association between neoplasia and highly cellular smears, the absence of colloid, the presence of microfollicles, large-cell dysplasia, prominent nucleoli or macronucleoli, coarse chromatin, nuclear grooves and inclusions, nuclear irregularity, and pleomorphism. The absence of colloid, high cellularity, > 25% of isolated HC, the presence of tridimensional groups, transgressing vessels, nuclear irregularity, prominent nucleoli or macronucleoli, coarse chromatin, hyperchromatism, pleomorphism, and diffuse large-cell dysplasia were features significantly associated with malignancy. Conclusions: No cytological feature alone can predict histological outcome, but all findings related to a neoplastic or malignant histology must be assessed. Individualized management protocols should be developed in each institution.

1.
Yazgan A, Balci S, Dincer N, Kiyak G, Tuzun D, Ersoy R, et al: Hürthle cell presence alters the distribution and outcome of categories in The Bethesda System for Reporting Thyroid Cytopathology. Cytopathology 2014; 25: 185–189.
2.
Shawky M, Sakr M: Hürthle cell lesion: controversies, challenges, and debates. Indian J Surg 2016; 78: 41–48.
3.
Samulski TD, Bai S, LiVolsi VA, Montone K, Baloch Z: Malignant potential of small oncocytic follicular carcinoma/Hürthle cell carcinoma: an institutional experience. Histopathology 2013; 63: 568–573.
4.
Yazgan A, Balci S, Dincer N, Ersoy PE, Tuzun D, Ersoy R, et al: Thyroid FNAC containing Hürthle cells and Hürthle-like cells: a study of 128 cases. J Cytol 2016; 33: 214–219.
5.
Auger M: Hürthle cells in fine-needle aspirates of the thyroid: a review of their diagnostic criteria and significance. Cancer Cytopathol 2014; 122: 241–249.
6.
Lloyd R, Osamura R, Klöppel G, Rosai J (eds): WHO Classification of Tumours of Endocrine Organs. Lyon, International Agency for Research on Cancer, 2017.
7.
McKee S, Wu H, Wang X, Cramer H, Lin J, Chen S: Hürthle cell neoplasms diagnosed by fine needle aspiration are not associated with an increased risk of malignancy. Acta Cytol 2014; 58: 235–238.
8.
Cibas ES, Ali SZ: The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009; 132: 658–665.
9.
Canberk S, Griffin AC, Goyal A, Wang H, Montone K, Livolsi V, et al: Oncocytic follicular nodules of the thyroid with or without chronic lymphocytic thyroiditis: an institutional experience. Cytojournal 2013; 10: 2.
10.
Kasaian K, Chindris A-M, Wiseman SM, Mungall KL, Zeng T, Tse K, et al: MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma. J Clin Endocrinol Metab 2015; 100:E611–E615.
11.
Wei S, LiVolsi VA, Montone KT, Morrissette JJD, Baloch ZW: PTEN and TP53 mutations in oncocytic follicular carcinoma. Endocr Pathol 2015; 26: 365–369.
12.
Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LGT, Liang Y, et al: Genomic dissection of Hürthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013; 98:E962–E972.
13.
Parikh PP, Allan BJ, Lew JI: Surgeon-performed ultrasound predictors of malignancy in patients with Hürthle cell neoplasms of the thyroid. J Surg Res 2013; 184: 247–252.
14.
Elliott DD, Pitman MB, Bloom L, Faquin WC: Fine-needle aspiration biopsy of Hürthle cell lesions of the thyroid gland. Cancer 2006; 108: 102–109.
15.
Yang GCH, Schreiner AM, Sun W: Can abundant colloid exclude oncocytic (Hürthle cell) carcinoma in thyroid fine needle aspiration? Cytohistological correlation of 127 oncocytic (Hürthle cell) lesions. Cytopathology 2013; 24: 185–193.
16.
Renshaw AA, Gould EW: Impact of specific patterns on the sensitivity for follicular and Hürthle cell carcinoma in thyroid fine-needle aspiration. Cancer Cytopathol 2016; 124: 729–736.
17.
Rossi ED, Martini M, Straccia P, Raffaelli M, Pennacchia I, Marrucci E, et al: The cytologic category of oncocytic (Hürthle) cell neoplasm mostly includes low-risk lesions at histology: an institutional experience. Eur J Endocrinol 2013; 169: 649–655.
18.
Straccia P, Rossi ED, Bizzarro T, Brunelli C, Cianfrini F, Damiani D, et al: A meta-analytic review of The Bethesda System for Reporting Thyroid Cytopathology: has the rate of malignancy in indeterminate lesions been underestimated? Cancer Cytopathol 2015; 123: 713–722.
19.
Lee KH, Shin JH, Ko ES, Hahn SY, Kim JS, Kim J-H, et al: Predictive factors of malignancy in patients with cytologically suspicious for Hürthle cell neoplasm of thyroid nodules. Int J Surg 2013; 11: 898–902.
20.
Zivic R, Diklic A, Grujicic SS, Paunovic I, Vekic B, Perunovic R, Radovanovic DZV: Malignancy predictors in oxyphile thyroid tumors. JBUON 2016; 21: 1496–1500.
21.
Petric R, Besic H, Besic N: Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hürthle cell neoplasms of the thyroid gland. World J Surg Oncol 2014; 12: 282.
22.
Arduc A, Dogan BA, Tuna MM, Tutuncu Y, Isik S, Berker D, et al: Higher body mass index and larger waist circumference may be predictors of thyroid carcinoma in patients with Hürthle-cell lesion/neoplasm fine-needle aspiration diagnosis. Clin Endocrinol (Oxf) 2015; 83: 405–411.
23.
McIvor NP, Freeman JL, Rosen I, Bedard YC: Value of fine-needle aspiration in the diagnosis of Hürthle cell neoplasms. Head Neck 1993; 15: 335–341.
24.
Cibas ES, Ali SZ: The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017; 27: 1341–1346.
25.
Seethala RR, Baloch ZW, Barletta JA, Khanafshar E, Mete O, Sadow PM, et al: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. Mod Pathol 2018; 31: 39–55.
26.
Haigh PI, Urbach DR: The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery 2005; 138: 1152–1158.
27.
Giorgadze T, Rossi ED, Fadda G, Gupta PK, LiVolsi VA, Baloch Z: Does the fine-needle aspiration diagnosis of  Hürthle-cell neoplasm/follicular neoplasm with oncocytic features? denote increased risk of malignancy? Diagn Cytopathol 2004; 31: 307–312.
28.
Donatini G, Beaulieu A, Castagnet M, Kraimps J-L, Levillain P, Fromont G: Thyroid Hürthle cell tumors: research of potential markers of malignancy. J Endocrinol Invest 2016; 39: 153–158.
29.
Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, Malapelle U, et al: Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hürthle cell neoplasms. Cancer Cytopathol 2009; 117: 522–529.
30.
Monaco M, Chiappetta G, Aiello C, Federico A, Sepe R, Russo D, et al: CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas). Eur Thyroid J 2014; 3: 211–216.
31.
Wu HH-J, Clouse J, Ren R: Fine-needle aspiration cytology of Hürthle cell carcinoma of the thyroid. Diagn Cytopathol 2008; 36: 149–154.
32.
Pisanu A, Di Chiara B, Reccia I, Uccheddu A: Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes. World J Surg 2010; 34: 836–843.
33.
Renshaw AA: Hürthle cell carcinoma is a better gold standard than Hürthle cell neoplasm for fine-needle aspiration of the thyroid. Cancer 2002; 96: 261–266.
34.
Roh MH, Jo VY, Stelow EB, Faquin WC, Zou KH, Alexander EK, et al: The predictive value of the fine-needle aspiration diagnosis “suspicious for a follicular neoplasm, Hürthle cell type” in patients with Hashimoto thyroiditis. Am J Clin Pathol 2011; 135: 139–145.
35.
Yang YJ, Khurana KK: Diagnostic utility of intracytoplasmic lumen and transgressing vessels in evaluation of Hürthle cell lesions by fine-needle aspiration. Arch Pathol Lab Med 2001; 125: 1031–1035.
36.
Alaedeen DI, Khiyami A, McHenry CR: Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease. Surgery 2005; 138: 650–657.
37.
Cacchi C, Arnholdt HM, Haas CJ, Kretsinger H, Axt L, Märkl B: Galectin-3 and cyclin D3 immunohistochemistry and tumor dimensions are useful in distinguishing follicular oncocytic carcinomas from oncocytic adenomas of the thyroid. Int J Endocrinol 2015; 2015: 276854.
38.
Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW: Does Hürthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol 2006; 34: 330–334.
39.
Strazisar B, Petric R, Sesek M, Zgajnar J, Hocevar M, Besic N: Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland. J Surg Oncol 2010; 101: 582–586.
40.
Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh Q-Y, et al: Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid. World J Surg 2008; 32: 702–707.
41.
Melck A, Bugis S, Baliski C, Irvine R, Anderson DW, Wilkins G, et al: Hemithyroidectomy: the preferred initial surgical approach for management of Hürthle cell neoplasm. Am J Surg 2006; 191: 593–597.
42.
Kroeker T, Prisman E, Shah M, MacMillan C, Freeman J: Hürthle cell lesions – a retrospective review of final surgical pathology. Thyroid Disord Ther 2014; 3: 2.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.